Assertio Therapeutics (NASDAQ: ASRT) reported Q2 EPS of $0.02, $0.10 better than the analyst estimate of ($0.08). Revenue for the quarter came in at $28.8 million versus the consensus estimate of $27.87 million.

Guidance:

Outlook Update

CEO O’Grady said “Results through the second quarter are tracking well with our full-year guidance as we enhance growth and profit potential, focus investment on our core assets and generate cash to support new growth drivers. We are narrowing our guidance ranges for Net Product Sales and EBITDA to reflect first half performance, the decision to cease commercialization of Otrexup, and improved operational efficiencies.”

Updated
$108.0 Million to $123.0 Million Adjusted EBITDA (Non-GAAP) $11.0 Million to $19.0 Million

For earnings history and earnings-related data on Assertio Therapeutics (ASRT) click here.